Literature DB >> 15633136

Stool screening for colorectal cancer: molecular approaches.

Neal K Osborn1, David A Ahlquist.   

Abstract

Assay of molecular markers in stool represents a promising noninvasive approach to screen colorectal cancer. Given that neoplasms exfoliate abundantly into the lumen and that DNA recovered from stool can be assayed with sensitive techniques, there is a strong biologic rationale to pursue this emerging technology. A challenge with DNA-based testing relates to the selection of markers. Because of the molecular heterogeneity of cancer, no single marker has yielded perfect sensitivity. Several combinations of markers in early stool assays have produced high detection rates of both colorectal cancer and advanced adenomas in selected patient groups, but observations from large representative populations are lacking at present. Potential expanded applications of stool DNA testing include detection of supracolonic aerodigestive cancers and of dysplasia in inflammatory bowel disease. Further marker discovery and technologic refinements should translate into improved test performance and fuel a continued evolution with this screening approach.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15633136     DOI: 10.1053/j.gastro.2004.10.041

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  53 in total

Review 1.  Colorectal cancer molecular biology moves into clinical practice.

Authors:  Colin C Pritchard; William M Grady
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

Review 2.  New trends in molecular and cellular biomarker discovery for colorectal cancer.

Authors:  Parisa Aghagolzadeh; Ramin Radpour
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

3.  Screening for colon cancer.

Authors:  J P Heiken
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

4.  Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening?

Authors:  G Ferretti; E Bria; P Carlini; A Felici; D Giannarelli; F Cuppone; P Papaldo; C Nisticò; A Fabi; A Gelibter; E Terzoli; F Cognetti
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 5.  Molecular alterations and biomarkers in colorectal cancer.

Authors:  William M Grady; Colin C Pritchard
Journal:  Toxicol Pathol       Date:  2013-10-31       Impact factor: 1.902

6.  Colorectal cancer and Crohn's colitis: clinical implications from 313 surgical patients.

Authors:  Stefano Scaringi; Carmela Di Martino; Daniela Zambonin; Marilena Fazi; Giuseppe Canonico; Francesca Leo; Ferdinando Ficari; Francesco Tonelli
Journal:  World J Surg       Date:  2013-04       Impact factor: 3.352

Review 7.  Colorectal cancer screening--optimizing current strategies and new directions.

Authors:  Ernst J Kuipers; Thomas Rösch; Michael Bretthauer
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

Review 8.  Genomic era diagnosis and management of hereditary and sporadic colon cancer.

Authors:  Edward David Esplin; Michael Paul Snyder
Journal:  World J Clin Oncol       Date:  2014-12-10

9.  Patient perceptions of stool DNA testing for pan-digestive cancer screening: a survey questionnaire.

Authors:  Dennis Yang; Shauna L Hillman; Ann M Harris; Pamela S Sinicrope; Mary E Devens; David A Ahlquist
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

10.  Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer.

Authors:  Y Hamaya; K Yoshida; T Takai; M Ikuma; A Hishida; S Kanaoka
Journal:  Br J Cancer       Date:  2010-02-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.